S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Join Morningstar today. It's Free.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|Idera Announces Publication of New Data Demonstrating Impact of Inhibiting TLRs 7, 8, and 9 in a Preclinical Model of Autoimmune Disease (2014/1/22)|
|Idera Pharmaceuticals Enters into Agreement with NCI to Evaluate Use of TLR Antagonists for the Treatment of Genetically Defined Lymphomas ()|
|Boston Scientific Reports Key Data At ACC 2014 For Cardiac Resynchronization Therapy Technology, Platinum Chromium Stents And Lotus™ Valve System (2014/4/1)|
|Idera Presents Preclinical Data at AACR Showing IMO-8400 Inhibits Tumor Growth and Survival Signaling in B-cell Lymphoma Cells with Oncogenic MYD88 L265P Mutation (2014/4/7)|
|Idera Pharmaceuticals Reports Second Quarter 2013 Financial Results and Corporate Highlights ()|
|Idera Pharmaceuticals Announces Positive Top-line Data in Phase 2 Trial of IMO-8400 (2014/3/28)|
|Idera to Provide Update on Programs at Stifel Nicolaus Healthcare Conference ()|
|Idera Pharmaceuticals Announces Expansion of Pipeline into Two Orphan Autoimmune Diseases (2014/3/13)|
|Idera Pharmaceuticals Reports Third Quarter 2013 Financial Results and Provides Corporate Update (2013/11/14)|
|Idera Pharmaceuticals Opens Enrollment for Phase 1/2 Clinical Trial of IMO-8400 in Waldenström’s Macroglobulinemia ()|
Click above to view more mutual fund data and stats for tlr - Teslin River Resources Corp.